| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author Reply
|
Brazier, John
|
|
|
26 |
3 |
p. 437-440
|
artikel
|
| 2 |
Copyright/Subscription
|
|
|
|
26 |
3 |
p. iv
|
artikel
|
| 3 |
Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non–Small Cell Lung Cancer in the Irish Healthcare Setting
|
Chu, Ryan Wong
|
|
|
26 |
3 |
p. 402-410
|
artikel
|
| 4 |
Does the United States Need Better Policies Governing Generic Drug Use?
|
McElwee, Newell E.
|
|
|
26 |
3 |
p. 392-393
|
artikel
|
| 5 |
Drug Pricing Throughout the Product Lifecycle: A Work in Progress
|
Mauskopf, Josephine A.
|
|
|
26 |
3 |
p. 317-319
|
artikel
|
| 6 |
Editorial Board
|
|
|
|
26 |
3 |
p. v
|
artikel
|
| 7 |
Equitable Prioritization of Health Interventions by Incorporating Financial Risk Protection Weights Into Economic Evaluations
|
Hendrix, Nathaniel
|
|
|
26 |
3 |
p. 411-417
|
artikel
|
| 8 |
How Much Does the US Public Value Equity in Health? A Systematic Review
|
Khor, Sara
|
|
|
26 |
3 |
p. 418-426
|
artikel
|
| 9 |
Innovative Public Price Mechanisms for Market Access of Innovative Medicines: A Marriage Between Cost-Effectiveness, Medical Need, and Budget Impact
|
Annemans, Lieven J.P.
|
|
|
26 |
3 |
p. 400-401
|
artikel
|
| 10 |
Measuring Health and Well-Being: We Need to Get it Right for Patients, With Patients
|
Perfetto, Eleanor M.
|
|
|
26 |
3 |
p. 435-437
|
artikel
|
| 11 |
Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions
|
Sullivan, Sean D.
|
|
|
26 |
3 |
p. 394-399
|
artikel
|
| 12 |
Modeling Tiered Pricing Frameworks: A Simulation Approach
|
Moradpour, Javad
|
|
|
26 |
3 |
p. 351-358
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
26 |
3 |
p. i-iii
|
artikel
|
| 14 |
The “Affordable Medicines” Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation
|
Dobrova, Viktoriia
|
|
|
26 |
3 |
p. 359-369
|
artikel
|
| 15 |
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom
|
Berdud, Mikel
|
|
|
26 |
3 |
p. 328-335
|
artikel
|
| 16 |
The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies
|
Cohen, Joshua T.
|
|
|
26 |
3 |
p. 344-350
|
artikel
|
| 17 |
The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics
|
Kogut, Stephen J.
|
|
|
26 |
3 |
p. 378-383
|
artikel
|
| 18 |
The Value of Medical Innovation Versus Industry Rewards
|
Hult, Kristopher J.
|
|
|
26 |
3 |
p. 320-327
|
artikel
|
| 19 |
The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price
|
Mladsi, Deirdre
|
|
|
26 |
3 |
p. 384-391
|
artikel
|
| 20 |
Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review
|
Khambholja, Kapil
|
|
|
26 |
3 |
p. 427-434
|
artikel
|
| 21 |
Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone
|
Rome, Benjamin N.
|
|
|
26 |
3 |
p. 370-377
|
artikel
|
| 22 |
Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the “Age of Cures” and Their Implications for Dynamic Efficiency
|
Garrison Jr., Louis P.
|
|
|
26 |
3 |
p. 336-343
|
artikel
|
Tijdschrift beschrijving